When time is measured in days and months instead of years and decades, perspectives on life tend to change.
For Libby Gaymon, a Cheektowaga woman who is battling a second attack of metastasized breast cancer, time is both friend and foe. Gaymon, 42, makes sure that whenever she is feeling well enough to get out of bed, she gets outside and cherishes her surroundings. She takes time to enjoy the little things in life – the flowers, the walk to the bus stop, even the dandelions sprouting through the cracks in the sidewalk. She appreciates how quickly life can pass you by.
Play Video
Play
Mute
Current Time 0:00
/
Duration Time 0:00
Loaded: 0%
Progress: 0%
Stream TypeLIVE
Remaining Time -0:00
Playback Rate
1
- Chapters
Chapters
- descriptions off, selected
Descriptions
- subtitles off, selected
Subtitles
- captions settings, opens captions settings dialog
- captions off, selected
Captions
Audio Track
Fullscreen
This is a modal window.
Caption Settings Dialog
Beginning of dialog window. Escape will cancel and close the window.
TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque
Font Size50%75%100%125%150%175%200%300%400%
Text Edge StyleNoneRaisedDepressedUniformDropshadow
Font FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps
DefaultsDone
Gaymon doesn’t know how much time she has left; she can feel the cancer spreading throughout her arms and legs. She had radiology on her skull to relieve the swelling from lesions.
“I’ve tried several chemos and every one of them has failed me. [The cancer] just keeps growing and growing,” Gaymon told 7 Eyewitness News from her living room, wearing a headscarf to conceal her bald head.
Gaymon is now trying an experimental immunotherapy treatment at Roswell Park. Immunotherapy helps the body’s immune system attack cancer cells. It is still being studied nationwide to see if it can play a role in treating metastatic breast cancer.
“With existing immunotherapies, we’ve seen a response rate of about 20%. We certainly, as a field, hope to improve on that percentage with newer combinations and approaches that are just beginning to be studied, like the one we are looking at for Libby,” Dr. Ellis Levine, Chief of Breast…
Recent Comments